Canaccord Upgrades Biogen To Buy On 'Decent Shot' Of Alzheimer's Approval
January 27, 2020 at 09:16 AM EST
Canaccord Genuity analyst Sumant Kulkarni upgraded Biogen to Buy from Hold with a price target of $360, up from $305.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|